BETAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAGAN is an ophthalmic solution approved in 1985 for treatment of glaucoma and ocular hypertension. As a small-molecule beta-blocker eye drop, it works by reducing intraocular pressure through non-selective beta-adrenergic receptor antagonism. The drug is now approaching loss of exclusivity in a mature ophthalmology market.
LOE Approaching
As an aging brand with LOE approaching, the team is likely focused on defensive strategies and transition planning rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BETAGAN offers limited career trajectory; the product is in defensive maintenance mode with approaching LOE. Roles are primarily commercial and compliance-focused rather than development-oriented, suitable for professionals seeking stability over growth.
Brand ManagerField Sales Representative
Worked on BETAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.